Safety and Tolerability of NNC0114-0006 Following Multiple s.c. Dosing at Escalating Dose Levels in Subjects With Rheumatoid Arthritis
Phase of Trial: Phase I
Latest Information Update: 10 Feb 2017
At a glance
- Drugs Anti-interleukin-21 monoclonal antibody (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 07 Jun 2017 Biomarkers information updated
- 01 Oct 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.